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Background: The appropriateness of the routine performance of an oral glucose tolerance test (OGTT) to screen
for diabetes mellitus (DM) during acute coronary syndrome hospitalization is still under debate.
Methods: A systematic search of databases (MEDLINE [1985 to March 2012], EMBASE [1985 to March 2012]) was
conducted. All prospective cohort studies assessing the accuracy or reproducibility of an OGTT in ACS or non-ACS
individuals were included. A bivariate model was used to calculate the pooled sensitivity (SEN), specificity (SPE),
positive likelihood ratio (PLR), negative likelihood ratio (NLR), and diagnostic odds ratio (DOR). Heterogeneity was
explored using subgroup analysis and meta-regression.
Results: Fifteen studies with 8,027 participants were included (10 ACS and 5 non-ACS studies). The pooled results
on SEN, SPE, PLR, NLR, and DOR were 0.70 (95% CI, 0.60-0.78), 0.91 (95% CI, 0.86-0.94), 7.6 (95% CI, 4.9-11.7), 0.33
(95% CI, 0.25-0.45), and 23 (95% CI, 12–41), respectively. The OGTT has a slightly lower SPE in diagnosing DM in ACS
than in non-ACS patients (0.86 [95% CI 0.81-0.92] versus 0.95 [95% CI 0.93-0.98], p<0.01), while the SEN values are
comparable (0.71 [95% CI 0.60-0.82] versus 0.67 [95% CI 0.54-0.81], p=0.43). After adjusting the interval between
repeated tests and age, the meta-regression did not show a difference in DOR between ACS and non-ACS studies.
Conclusions: Despite the discrepancy in the interval between the two OGTTs, performing an OGTT in patients with
ACS provides accuracy that is similar to that in in non-ACS patients. It is reasonable to screen patients hospitalized
for ACS for previously undiagnosed DM using an OGTT.
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Numerous studies have demonstrated that hyperglycemia
is common among patients with acute coronary syndrome
(ACS) [1,2], and the relationship between hyperglycemia
and increased mortality risk in ACS has been well estab-
lished across various glucose metrics [3,4].
However, considering its accuracy and reproducibility in
stress condition, the routine performance of an oral glucose
tolerance test (OGTT) to diagnose diabetes during the* Correspondence: Zhangebmg@gmail.com
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reproduction in any medium, provided the oracute phase of ACS is still the subject of ongoing debate.
The European guidelines on diabetes, pre-diabetes, and car-
diovascular diseases recommend the performance of an
OGTT in patients with established cardiovascular disease
[5]. Furthermore, the European guidelines on the manage-
ment of acute myocardial infarction in patients presenting
with persistent ST-segment elevation specify that an OGTT
should be performed before or shortly after hospital dis-
charge [6]. In regards to the management of hyperglycemia
in ACS, the NICE (National Institute for Health and Clin-
ical Excellence) does not recommend the routine use of the
OGTT in patients with hyperglycemia after ACS without
known diabetes if hemoglobin A1C and fasting blood glu-
cose levels are within the normal range [7]. A scientificThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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Committee of the Council on Nutrition, Physical Activity,
and Metabolism does not encourage routine use of the
OGTT for screening during the hospital stay [8].
Thus, this meta-analysis of prospective cohort studies
to determine the accuracy of the OGTT in the diagnosis
of diabetes in the acute phase of ACS compared to that
in non-ACS cases was conducted to clarify this dispute
with evidence.Methods
A protocol was designed that detailed the objective of
our analysis, the criteria for study inclusion/exclusion,
the assessment of study quality, the primary outcome,
and the statistical methods in accordance with the
MOOSE guideline for meta-analysis of observational
studies [9].Data sources and searches
A search of MEDLINE (1985 to March 2012) and EMBASE
(1985 to March 2012) via EMBASE.com was conducted to
identify all studies involving diagnostic tests assessing the
value of the OGTT in the diagnosis of diabetes mellitus in
subjects with or without ACS (Additional file 1) (Yicong Ye
and Hongzhi Xie). In addition, a manual search of the lit-
erature using the references of original manuscripts,
reviews, and meta-analyses was performed. Finally, a search
of the Cochrane database of ongoing systemic reviews was
conducted. No language restriction was imposed.Study selection
The study eligibility was independently determined by two
reviewers (Yicong Ye and Hongzhi Xie). Disagreement
was resolved by consensus. The study eligibility criteria
included: 1) published prospective cohort studies, 2) per-
forming the first OGTT during ACS hospitalization (only
for ACS studies), 3) repeating an OGTT more than 1
week and less than 3 years after the first one, and 4) use of
a 75 g OGTT.
The following were criteria for exclusion: 1) pregnant
and pediatric individuals, 2) patients with other chronic
diseases, other than coronary heart disease, such as cys-
tic fibrosis, polycystic ovary syndrome, acromegaly, liver
disease, and renal disease, 3) studies in which the OGTT
was repeated only in subjects with abnormal or normal
OGTT results in the first test, and 4) studies with
intended medical intervention (life-style change or medi-
cation) between administration of the two OGTTs.
Attempts were made to contact the author for further
information on studies that fulfilled the above criteria
but did not have sufficient data to build a two-by-two
table before they were excluded from the final analysis.Data extraction and quality assessment
Data extraction was carried out independently by two
authors (Yicong Ye and Hongzhi Xie). Disagreements
were resolved by discussion between the two reviewing
authors. From each included trial, information was
extracted on: 1) the study population, 2) the published
language, 3) the time interval between administration of
the two OGTTs, 4) the reference standard of diabetes,
5) mean age of study population and 6) the true positive
value, false positive value, false negative value, and true
negative value of each included study.
Study quality was assessed using the QUADAS list,
with each item scored as “yes”, “no”, or “unclear” [10].
The results are presented in the text and in a graph. A
summary score was not calculated when estimating the
overall quality of an article since the interpretation of
such summary scores is problematic and potentially mis-
leading. The items in the QUADAS tool and their inter-
pretation are presented in Additional file 1.
Data synthesis and analysis
The WHO (World Health Organization) 1985 [11],
ADA (American Diabetes Association) 2003 [12], or
WHO 1999 [13] criteria was used as the reference stand-
ard depending on which criteria had been used in each
study. All the included patients can be classified into
two groups: diabetes and non- diabetes. The diagnostic
threshold was the same as the reference standard in each
included study. Accordingly, the two-by-two tables were
constructed. The data in the two-by-two tables were
used to calculate the sensitivity and specificity for each
study. The individual study results were presented
graphically by plotting the estimates of sensitivity (SEN)
and specificity (SPE), and their 95% confidence intervals
(95% CI), in paired forest plots.
A bivariate model was used for the meta-analysis of
the pairs of SEN and SPE and for the construction of a
summary receiver operating characteristic (ROC) curve
[14]. This summary ROC curve represents the change in
diagnostic accuracy according to changes in the cutoff
value. The bivariate random effects approach enabled
the calculation of summary estimates of SEN, SPE, the
positive likelihood ratio (PLR), the negative likelihood
ratio (NLR), and the diagnostic odds ratio (DOR) while
correctly dealing with the different sources of variation:
(1) the imprecision by which SEN and SPE were mea-
sured within each study, (2) variation beyond chance in
SEN and SPE between studies, and (3) any correlation
that might exist between SEN and SPE.
The heterogeneity (or absence of homogeneity) of the
results between studies was assessed statistically using the
quantity I2, which describes the percentage of total variation
across studies that is attributable to heterogeneity rather
than chance [15]. Covariates were incorporated in the
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of heterogeneity across subgroups of studies. Due to the bi-
variate nature of the model, the effects of covariates on
SEN and SPE can be modeled separately. The following
covariates were analyzed to explore the heterogeneity:
1) Study population: the major objective of the studies
was to compare the diagnostic accuracy in patients with
and without ACS; 2) Threshold: although different cri-
teria were used in the studies (including WHO 1985,
ADA 2003, and WHO 1999), all studies used the same
cutoff value of a 2-hour OGTT (11.1mmol/L) to diagnose
diabetes. The major difference is that some of the studies
included FBG in the diagnosis criteria, while others did
not. Thus, the studies were divided into 2 subgroups (with
or without FBG). 3) Blood sample: different reproducibility
values for plasma and capillary glucose have been reported.
4) Interval between repeated tests (within 2 months versus
more than 2 months): a prolonged interval between two
OGTTs may also lead to poor reproducibility even though
the optimal interval is still unknown. 5) Age: aging is asso-
ciated with degradation of the pancreatic β-cells which




Wei et al. 2011 ACS* English WHO¶1999 (2hOGTT**
+FBG††)
Ilany et al. 2011 ACS English Unknown (2hOGTT+FB
Bronisz et al. 2011 STEMI† English WHO1999 (2hOGTT)
Jimenez-Navarro
et al. 2010
PCI‡ (ACS 80%) English WHO1999 (2hOGTT)
Lewczuk et al.
2009
ACS Polish Unknown (2hOGTT+FB
Knudsen et al.
2009
STEMI English WHO1999 (2hOGTT+FB
Srinivas-Shankar
et al. 2008
NSTEMI English WHO1999 (2hOGTT+FB
Lankisch et al.
2008
AMI§ English WHO1999 (2hOGTT+FB
Choi et al. 2005 AMI English WHO1999 (2hOGTT+FB
Tenerz et al. 2003 AMI English WHO1999 (2hOGTT+FB













Ko et al. 1998 General
population
English WHO1985 (2hOGTT+FB




*Acute coronary syndrome; †ST-elevation myocardial infarction; ‡Percutaneous coro
||Coronary artery bypass graft; ¶World Health Organization; #American Diabetes Asso
††Fasting blood glucose; ‡‡TP: True positive; FP: False positive; FN: False negative; TNMeta-regression was conducted to further explore the
heterogeneity quantitatively among the studies and to
determine the diagnostic accuracy of the OGTT in dif-
ferent conditions. The lnDOR was used as the
dependent variable. The standard error of the lnDOR
was used to measure the within-study variability, and
the residual maximum likelihood method to estimate
the between-study variance. Factors associated with sig-
nificantly different SEN and/or SPE in the subgroup
analysis were included in the meta-regression model as
covariates.
The potential publication bias was assessed using the
Deeks funnel plots [16]. The studies by Eschwege et al.
and De Vegt F et al. had much larger sample sizes and
much longer intervals between the administrations of
the two OGTTs, compared with the other studies
included in the meta-analysis (Table 1). In order to as-
sess the effect of this study on the pooled result, a post-
hoc sensitive analysis was performed to calculate DOR
for ACS in the meta-regression model without the
studies by Eschwege et al. and De Vegt F et al. In






TP‡‡ FP FN TN
>1 week 65.6 Plasma 94 23 4 0 67
G) 3-24 months 57 Plasma 29 0 10 1 18
3 months 56.5 Plasma 200 8 20 2 170
1 months 60.8 Capillary 88 9 21 7 51
G) 12 months 51.9 Plasma 69 14 3 5 47
G) 3 months 58 Plasma 201 5 17 5 174
G) 3 months 65 Plasma 49 3 3 2 41
G) 3 months 62.7 Plasma 62 11 8 8 35
G) 3 months 60.1 Plasma 30 7 3 2 18
G) 3 months 63.2 Capillary 142 25 22 10 85
G) 2-3 weeks NA Plasma 259 30 17 8 204
G) 30 months 50 Plasma 5400 105 102 171 5022
G) 2-6 weeks 61.7 Plasma 1109 85 25 31 968
G) 6 weeks 41 Plasma 212 24 17 56 115
G) 10 days 56.8 Plasma 81 9 5 3 64
nary intervention; §Acute myocardial infarction;
ciation; **Oral glucose tolerance test;
: True negative.
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has varied. Another post-hoc sensitive analysis was per-
formed in order to calculate DOR for ACS in the meta-
regression model without the study using the 1985
WHO criteria.
All analyses were performed using STATA version 11.0
(Stata Corp; College Station, TX). All statistical tests
were two-sided, with a p value of 0.05 denoting statis-
tical significance.Results
Characteristics and methodological quality of included
studies
Of the 5,521 references identified in the initial search,
only 18 reports fulfilled the criteria for inclusion in the
meta-analysis. After communicating with the authors, 15
reports offered sufficient data to build a two-by-two
table and thus were included in the final meta-analysis
(Figure 1) [17-31]. Of the 15 included studies involving
8,027 subjects, 10 studies included patients with ACS, and
the remaining consisted of non-ACS individuals. The
characteristics of the included studies are detailed in
Table 1. The results on the methodological quality of the
included studies are presented in text form in Additional
file 1 and in a graph in Figure 2.Figure 1 Flowchart of study selection. NGT: normal glucose tolerance. OPooled results and hierarchic summary ROC curve
The SEN of the included studies ranged from 0.38 to
0.96, whereas the SPE ranged from 0.64 to 0.98 (forest
plots in Figure 3). The hierarchical summary ROC curve
represents the relationship between sensitivity and speci-
ficity across the included studies with a 95% confidence
ellipse and a 95% prediction ellipse (Figure 4). The area
under the summary ROC curve (AUC) was 0.87 (95% CI,
0.16-1.00). Using the bivariate model, the pooled results
for SEN, SPE, PLR, NLR, and DOR were 0.70 (95% CI,
0.60-0.78), 0.91 (95% CI, 0.86-0.94), 7.6 (95% CI, 4.9-11.7),
0.33 (95% CI, 0.25-0.45), and 23 (95% CI, 12–41), respect-
ively. The I2 value of all measures was 99% (95% CI,
98-99%), indicating significant heterogeneity across the
included studies.Subgroup analysis, meta-regression and publication bias
The subgroup analyses demonstrated that the OGTT
performed in ACS patients has similar SEN (0.71 [95%
CI, 0.60-0.82] versus 0.67 [95% CI, 0.54-0.81], p=0.43)
but a slightly lower SPE (0.86 [95% CI, 0.81-0.92] versus
0.95 [95% CI, 0.93-0.98], p<0.01) compared with non-
ACS patients. A prolonged interval between repeated
tests (more than 2 months) is also associated with lower
SEN (0.62 [95% CI, 0.50-0.73] versus 0.77 [95% CI, 0.68-GTT: oral glucose tolerance test.
Figure 2 Risk of bias.
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0.92 [95% CI, 0.87-0.97], p<0.01). Compared with the
younger age (< 60 years) group, advanced age (≥60
years) is associated with lower SPE (0.89 [95% CI, 0.82-
0.96] versus 0.92 [95% CI, 0.87-0.97], p=0.01) while the
SEN is similar (0.73 [95% CI, 0.62-0.84] versus 0.63 [96%
CI, 0.48-0.77], p=0.81). However, using a different
threshold (2-hour OGTT with or without FBG) or blood
sample (plasma glucose or capillary glucose) did not lead
to different diagnostic accuracy (all p>0.05) (Figure 5).
Since ACS, interval between repeated tests and age
were found to be associated with different SEN and/or
SPE in the subgroup analysis, multiple meta-regressions
were performed to further determine the effect of these
factors on the DOR. However, none of these covariants
was found to be associated with different diagnostic ac-
curacy in the multiple meta-regression model (Table 2).
The Deeks funnel plot asymmetry test showed insig-
nificant publication bias (p=0.24, Figure 6).
The post hoc sensitive analysis, which excluded the
largest studies by Eschwege et al. and De Vegt et al.,
demonstrated a similar result (DOR 0.91, 95% CI 0.02-
47.95, p=0.955), indicating the final conclusion of our
meta-analysis was not markedly affected by these stud-
ies. Another post hoc sensitive analysis excluded studiesusing the 1985 WHO criteria also demonstrated a result
similar to the final conclusion of the meta-analysis
(DOR 0.53, 95% CI 0.01-19.36, p=0.687).
Discussion
The role of the OGTT in the diagnosis of diabetes in the
general population has been the subject of debate for
decades due to the test’s poor reproducibility, which is
mainly caused by random variants in glucose metabol-
ism. Thus, it is necessary to take the reproducibility of
the OGTT into consideration when evaluating the use
of the test in ACS. To the best of our knowledge, this is
the first meta-analysis designed to evaluate the accuracy
of the OGTT in ACS and to compare it with that in
non-ACS cases. In patients with ACS, OGTT has a
slightly lower SPE in diagnosing diabetes compared with
those without ACS, while the SEN values are compar-
able. A lower SPE (true negative rate) indicates that per-
forming an OGTT in patients with ACS will result in a
higher proportion of false positive results. According to
the result of the subgroup analysis, less than one in
every 10 ACS patients diagnosed with diabetes using an
OGTT before discharge will have a different result at
the follow-up OGTT resulting in a change in diagnosis.
After adjusting the interval between repeated tests and age
Figure 3 Paired forest plots of sensitivity and specificity. ACS: acute coronary syndrome.
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OGTT in ACS patients was not associated with lower
diagnostic accuracy compared with non-ACS patients.
This means that it is reasonable to perform an OGTT to
screen for diabetes in patients with ACS before discharge.
It is believed that aging is associated with function of
the pancreatic β cells, which may affect the accuracy of
OGTT. In the subgroup analysis, advanced age (≥60
years) was associated with lower SPE, while the SEN is
similar when compared with the younger age (< 60
years) group. The younger patients, with well preserved
function of the pancreatic β cells, maintained their
plasma glucose in normal range in the setting of stress
and only those with previous unknown DM could be
identified during ACS. On the other hand, due to com-
promised function of the pancreatic β cells, the patients
of advanced age were unable to maintain the plasma glu-
cose level during the stress and the plasma glucose
returned to the normal range only after the stress was
eliminated, which made the OGTT less accurate in
patients of advanced age enduring ACS. However, the ef-
fect of age on the accuracy of OGTT during ACS is not
observed when using the meta-regression model.
Due to the poor reproducibility of the OGTT, it may
be reasonable to repeat the test after discharge, which isalso recommended in the WHO 1999 criteria [13]. Al-
though the optimal time to repeat an OGTT is still un-
known, OGTT could be repeated in 3 months after
hospital discharge if necessary, given most of the studies
repeated the OGTT 3 months after discharge.
Hyperglycemia during ACS was thought to be “stress
hyperglycemia”, which develops due to a highly complex
interplay between hormones (such as catecholamines,
growth hormones, and cortisol) and cytokines, ultim-
ately leading to excessive hepatic glucose production
and insulin resistance [32]. A study by Choi et al.
showed that acute myocardial infarction (MI) patients
with IGT or diabetes exhibited higher levels of high-
sensitivity C-reactive protein and interleukin-6 levels
compared with acute MI patients with normal glucose
tolerance or well-controlled diabetes, indicating that gly-
col metabolism in acute MI is associated with acute
stress and inflammation [26]. However, this finding was
not supported by the other studies included in this
meta-analysis. Neither C-reactive protein nor the extent
of myocardial damage was found to be related to hyper-
glycemia in ACS patients [21,23,24]. Thus, the evidence
of stress hyperglycemia in ACS is still equivocal.
It is well-known that in-hospital hyperglycemia is asso-
ciated with both the short-term and long-term prognosis
Figure 4 Hierarchical summary receiver operating characteristic (SROC) curve. AUC: area under curve.
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on admission, fasting plasma glucose or HbA1c, in non-
diabetic patients with AMI are not sensitive enough to
uncover previously undiagnosed abnormal glucose toler-
ance or diabetes [35-37]. Furthermore, previous studies
have indicated that the 2-h post challenge plasmaFigure 5 Subgroup analysis (sensitivity and specificity). ACS: acute corglucose level was a significant predictor of cardiovascu-
lar events in patients with previous MI [38] and the
prognosis of AMI patients with a new diagnosis of dia-
betes or impaired glucose tolerance defined by an
OGTT during hospitalization was significantly worse than
that of patients with impaired fasting glucose and normalonary syndrome FBG: fasting blood glucose.
Table 2 Results of multiple meta-regression
Variants DOR 95% CI for DOR p value
Acute coronary syndrome 0.27 0.03-2.33 0.21
Interval between repeated tests 0.79 0.13-4.75 0.78
Age 1.04 0.91-1.19 0.51
Tau2 (estimate of between-study variance) = 0.89.
Residual I2 (percentage of residual variation due to heterogeneity) = 63.49%.
Adjusted R2 (proportion of between-study variance explained) = 12.10%.
Model F = 1.10, P = 0.39.
*Diagnostic odds ratio.
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cemia, but whose 2-hour plasma glucose concentrations
did not return to the FPG levels during an OGTT have
been shown to have increased risk of cardiovascular dis-
eases [42]. Thus, early performance of OGTT during the
AMI hospitalization may provide an opportunity to detect
the high risk population and establish the undiagnosed
diabetes or impaired glucose tolerance. A recent study has
shown that discontinuation of anti-hyperglycemic therapy
during AMI hospitalization is common and associated
with higher mortality rates after discharge in older
patients [43]. Early diagnosis of diabetes during AMI
hospitalization may be vital to improve compliance with
life style changes or anti-hyperglycemic therapy.
Studies of repeated OGTT performed only in patients
with abnormal or normal OGTT results in the first test
were excluded from this meta-analysis, since theseFigure 6 Deeks funnel plot asymmetry test of publication bias.studies may lead to underestimation or overestimation
of the accuracy of OGTT. Studies with intended med-
ical intervention between the two OGTTs were also
excluded, because several interventions such as exer-
cise and medication have been shown to be associated
with improved glucose tolerance.
The use of the hemoglobin A1C test to diagnose DM,
with a threshold of 6.5%, had been recommended by ADA
2010 criteria due to its stability and convenience [44]. Re-
cently, Ramachandran et al. divided newly diagnosed DM
patients with ACS into two groups based on A1C level: un-
diagnosed preexisting diabetes was considered possible if
the hemoglobin A1C values were ≥6.0%, and stress hyper-
glycemia was considered if the hemoglobin A1C values
were <6.0%. Surprisingly, after 3 months, all of the undiag-
nosed preexisting diabetes patients remained diabetic, while
only 16.7% of the stress hyperglycemia patients remained
diabetic [45]. Thus, new consensus statements on the care
of the hyperglycemia in ACS patients have recommended
its use during hospitalization with an OGTT [46].
The studies have several limitations. First, even though
the analysis identified statistically insignificant publication
bias, all of the articles that fulfilled the inclusion criteria
were not included because some authors were unwilling
to offer the original data and there may be data relevant to
this topic which have never been published. Second, these
findings are based on an indirect comparison of two
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cibility of the OGTT between ACS and non-ACS patients
was available in a single study. Finally, this is a meta-
analysis of study level, instead of individual level, which
makes it impossible for us to determine the optimal timing
for OGTT during hospitalization.
Conclusion
Based on the meta-analysis, performing an OGTT in
ACS has similar diagnostic accuracy with that in non-
ACS cases. It is reasonable to use the OGTT to screen
for diabetes during the hospital stay of ACS patients.
Further studies should focus on the optimal timing of
OGTT during ACS hospitalization.
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